Drug manufacturers are once again facing new state limits on marketing and interactions with healthcare providers. Manufacturers should review the new laws and regulations carefully, consider how they might engage with the agencies interpreting the new limits, and begin preparing their own compliance efforts.
Please see full publication below for more information.
